Cargando…
Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials
BACKGROUND: Detailed toxicity data are routinely collected in breast cancer (BC) clinical trials. However, ovarian toxicity is infrequently assessed, despite the adverse impacts on fertility and long-term health from treatment-induced ovarian insufficiency. OBJECTIVES: To determine the barriers to a...
Autores principales: | Cui, Wanyuan, Phillips, Kelly-Anne, Francis, Prudence A., Anderson, Richard A., Partridge, Ann H., Loi, Sherene, Loibl, Sibylle, Keogh, Louise |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127191/ https://www.ncbi.nlm.nih.gov/pubmed/35597179 http://dx.doi.org/10.1016/j.breast.2022.05.002 |
Ejemplares similares
-
Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies
por: Rosario, Roseanne, et al.
Publicado: (2022) -
Understanding the facilitators and barriers of antiretroviral adherence in Peru: A qualitative study
por: Curioso, Walter H, et al.
Publicado: (2010) -
PIK3CA mutations in breast cancer: reconciling findings from preclinical and
clinical data
por: Zardavas, Dimitrios, et al.
Publicado: (2014) -
Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy
por: Loi, Sherene
Publicado: (2013) -
Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer
por: O’Leary, Ben, et al.
Publicado: (2020)